Phuturdex › Diseases › Prostatic Neoplasms
Drugs in development · updated 30 October 2026
Prostatic Neoplasms: drugs in development
As of 30 October 2026 there are 522 active clinical trials (recruiting or ongoing, phases I–III) on 383 drugs for prostatic Neoplasms. 230 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 230 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AbirateroneZytiga, Yonsa® | II–III | 78 | NCT04787744 |
| EnzalutamideDeutenzalutamide, Xtandi | II–III | 70 | NCT04787744 |
| PrednisonePredinisone, Cortancyl | II–III | 52 | NCT04787744 |
| ApalutamideJNJ 56021927, Erleada® | II–III | 44 | NCT04787744 |
| DocetaxelTaxotere, Beizray® | II–III | 44 | NCT04787744 |
| DarolutamideNubeqa, ODM-201 | II–III | 42 | NCT07852195 |
| Leuprolide AcetateLeuprorelin, Lupron | II–III | 31 | NCT04787744 |
| Pluvicto177Lu-PSMA-617, Lutetium Lu 177 Vipivotide Tetraxetan | II–III | 27 | NCT07852195 |
| DegarelixFirmagon, Degarelix Accord® | II–III | 20 | NCT04787744 |
| CarboplatinCarboplatine, Paraplatin | III | 17 | NCT06439225 |
| RelugolixOrgovyx® | II–III | 16 | NCT04787744 |
| BicalutamideCasodex® | II–III | 15 | NCT04787744 |
| GoserelinZOLADEX | II–III | 15 | NCT04787744 |
| CabazitaxelJevtana Kit®, Jevtana® | II–III | 14 | NCT07852195 |
| TriptorelinTriptorelin Embonate, Triprorelin Acetate | II–III | 14 | NCT04787744 |
Sorted by most advanced phase and number of active trials. Showing 15 of 153 drugs.
All 383 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Castration-resistant prostatic neoplasm 44 drugs
- Bladder neoplasm 185 drugs
- Endometrial neoplasm 298 drugs
- Uterine cervix neoplasm 224 drugs
- Stomach neoplasm 340 drugs
- Pancreatic neoplasm 395 drugs
- Neoplasm 671 drugs
- Metastasis 493 drugs
- Non-small-cell lung carcinoma 726 drugs
- Sarcoma 204 drugs
- Melanoma 352 drugs
- Colorectal neoplasm 534 drugs
Broader categories
- Genital Diseases 7 drugs
- Urogenital Diseases 16 drugs
- Genital Neoplasms, Male 6 drugs
- Genital Diseases, Male 8 drugs
- Male urogenital disease 19 drugs
- Prostatic Diseases 8 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D011471 “Prostatic Neoplasms”.